SETD2 is also frequently mutated or under expressed in solid tumors such as breast tumors, pediatric high-grade gliomas, lung carcinomas, gastric/pancreatic ductal adenocarcinomas, and colorectal carcinomas but also leukemia and lymphoma. Here, SETD2 is linked to lung carcinoma.